Literature DB >> 11474248

Clinical value of thymidine kinase in patients with cervical carcinoma.

R Fujiwaki1, K Hata, M Moriyama, O Iwanari, H Katabuchi, H Okamura, K Miyazaki.   

Abstract

OBJECTIVE: Our purpose was to determine the clinical value of thymidine kinase (TK), which is an important pyrimidine pathway enzyme involved in salvage DNA synthesis, in patients with cervical carcinoma.
METHODS: We examined TK mRNA expression by reverse transcription polymerase chain reaction in 19 tissue specimens of invasive cervical carcinoma and 9 normal cervices and related it to thymidylate synthase (TS) and thymidine phosphorylase (TP) mRNA expressions. Serum TK level was determined by radioenzymatic assay in 79 patients with invasive cervical carcinoma, 7 patients with microinvasive carcinoma, 21 patients with carcinoma in situ and 32 normal women.
RESULTS: TK mRNA expression was upregulated in invasive cervical carcinoma compared with the normal cervix (p < 0.05) and significantly correlated with TS mRNA expression (p < 0.0001) but not with TP mRNA expression. The serum TK level was significantly higher in patients with invasive carcinoma than in normal women and patients with carcinoma in situ (p < 0.01 and p < 0.05). In patients with invasive cervical carcinoma, the serum TK level significantly correlated with TK mRNA expression (p < 0.05), but not with any conventional clinicopathologic factors. High serum TK levels significantly correlated with a poorer survival (p < 0.05), and multivariate analysis showed serum TK level to be an independent prognostic factor (p < 0.05).
CONCLUSION: TK may play an important role in influencing the malignant behavior of cervical carcinoma, and measurement of the serum TK level may be useful in predicting survival in patients with cervical carcinoma. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474248     DOI: 10.1159/000055352

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  10 in total

1.  Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.

Authors:  Charles A Kunos; Tomas Radivoyevitch
Journal:  Gynecol Obstet (Sunnyvale)       Date:  2011-12-10

2.  Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers.

Authors:  Charles A Kunos; Gina Ferris; Natalie Pyatka; John Pink; Tomas Radivoyevitch
Journal:  Radiat Res       Date:  2011-07-14       Impact factor: 2.841

3.  Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.

Authors:  Zhi-Heng Huang; Xing-Song Tian; Rong Li; Xian-Ming Wang; Wen Wen; Hong Guan; Ya-Jie Yang
Journal:  Exp Ther Med       Date:  2011-11-28       Impact factor: 2.447

4.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

5.  Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.

Authors:  Bao-Jin Wu; Wen-Peng Li; Cheng Qian; Wei Ding; Zhong-Wen Zhou; Hua Jiang
Journal:  Tumour Biol       Date:  2012-11-21

6.  Identification and validation of genes involved in cervical tumourigenesis.

Authors:  Thangarajan Rajkumar; Kesavan Sabitha; Neelakantan Vijayalakshmi; Sundersingh Shirley; Mayil Vahanan Bose; Gopisetty Gopal; Ganesharaja Selvaluxmy
Journal:  BMC Cancer       Date:  2011-02-22       Impact factor: 4.430

7.  Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia.

Authors:  Evita G Weagel; Wei Meng; Michelle H Townsend; Edwin J Velazquez; Rachel A Brog; Michael W Boyer; K Scott Weber; Richard A Robison; Kim L O'Neill
Journal:  Onco Targets Ther       Date:  2017-09-06       Impact factor: 4.147

8.  Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.

Authors:  Lena Carlsson; Anders Larsson; Henrik Lindman
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

9.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  Serum biomarkers for early detection of gynecologic cancers.

Authors:  Yutaka Ueda; Takayuki Enomoto; Toshihiro Kimura; Takashi Miyatake; Kiyoshi Yoshino; Masami Fujita; Tadashi Kimura
Journal:  Cancers (Basel)       Date:  2010-06-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.